164 related articles for article (PubMed ID: 6090834)
21. Suppressive effect of morphine on serum gonadotropin levels in castrated rats.
Muraki T; Tokunaga Y; Nakadate T; Kato R
Arch Int Pharmacodyn Ther; 1980 Aug; 246(2):324-34. PubMed ID: 6776920
[TBL] [Abstract][Full Text] [Related]
22. Identification of multiple opiate receptors through neuroendocrine responses. II. Antagonism of mu, kappa and sigma agonists by naloxone and WIN 44,441-3.
Pechnick R; George R; Poland RE
J Pharmacol Exp Ther; 1985 Jan; 232(1):170-7. PubMed ID: 2981314
[TBL] [Abstract][Full Text] [Related]
23. Increased analgesic potency of morphine and increased brain opioid binding sites in the rat following chronic naltrexone treatment.
Yoburn BC; Goodman RR; Cohen AH; Pasternak GW; Inturrisi CE
Life Sci; 1985 Jun; 36(24):2325-32. PubMed ID: 2989632
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the duration of action of nalmefene and naloxone on the hypothalamic-pituitary axis of the rhesus monkey.
VanVugt DA; Webb MY; Reid RL
Neuroendocrinology; 1989 Mar; 49(3):275-80. PubMed ID: 2716954
[TBL] [Abstract][Full Text] [Related]
25. Effects of a sustained-release naloxone pellet on luteinizing hormone secretion in female rats.
Gabriel SM; Simpkins JW
Neuroendocrinology; 1983 Nov; 37(5):342-8. PubMed ID: 6139759
[TBL] [Abstract][Full Text] [Related]
26. Development of tolerance to the effects of morphine on luteinizing hormone secretion as a function of castration in the male rat.
Cicero TJ; Meyer ER; Schmoeker PF
J Pharmacol Exp Ther; 1982 Dec; 223(3):784-9. PubMed ID: 7143239
[TBL] [Abstract][Full Text] [Related]
27. Effects of different opiates on hypothalamic monoamine turnover and on plasma LH levels in pro-oestrous rats.
Gopalan C; Gilmore DP; Brown CH
J Neurol Sci; 1989 Dec; 94(1-3):211-9. PubMed ID: 2559164
[TBL] [Abstract][Full Text] [Related]
28. Diurnal influences on serum luteinizing hormone responses to opiate receptor blockade with naloxone or to luteinizing hormone-releasing hormone in the immature female rat.
Blank MS; Mann DR
Proc Soc Exp Biol Med; 1981 Dec; 168(3):338-43. PubMed ID: 6275395
[No Abstract] [Full Text] [Related]
29. Development of acute tolerance to the effects of naloxone on the hypothalamic-pituitary-luteinizing hormone axis in the male rat.
Owens DP; Cicero TJ
J Pharmacol Exp Ther; 1981 Jan; 216(1):135-41. PubMed ID: 7005427
[TBL] [Abstract][Full Text] [Related]
30. Opioidergic modulation of in vitro pulsatile gonadotropin-releasing hormone release from the isolated medial basal hypothalamus of the male guinea pig.
Giri M; Kaufman JM
Endocrinology; 1994 Nov; 135(5):2137-43. PubMed ID: 7956937
[TBL] [Abstract][Full Text] [Related]
31. Morphine administration in the amygdala or periaqueductal central gray depress serum levels of luteinizing hormone.
Lakoski JM; Gebhart GF
Brain Res; 1982 Jan; 232(1):231-7. PubMed ID: 7055705
[TBL] [Abstract][Full Text] [Related]
32. Monoaminergic antagonists which block naloxone-induced release of luteinizing hormone bind selectively to hypothalamic opiate receptors.
Blank MS; Diez JA; Roberts DL
Brain Res; 1983 Nov; 279(1-2):153-8. PubMed ID: 6315167
[TBL] [Abstract][Full Text] [Related]
33. The paradoxical stimulatory effect of morphine on LH secretion is dose-dependent and naloxone-reversible.
Van Vugt DA; Baby N; Stewart M; Reid RL
Neuroendocrinology; 1989 Jul; 50(1):109-16. PubMed ID: 2755561
[TBL] [Abstract][Full Text] [Related]
34. In vivo and in vitro studies on the opioidergic control of the secretion of gonadotrophin-releasing hormone and luteinizing hormone in sexually immature and adult male rats.
Leposavic G; Cover PO; Buckingham JC
Neuroendocrinology; 1991 Jun; 53(6):579-88. PubMed ID: 1652110
[TBL] [Abstract][Full Text] [Related]
35. Paradoxical LH and prolactin responses to naloxone after chronic treatment with morphine.
Almeida OF; Schulz R; Herz A
J Endocrinol; 1986 Feb; 108(2):181-9. PubMed ID: 3950525
[TBL] [Abstract][Full Text] [Related]
36. Stimulatory and inhibitory effects of the opioids on gonadotropin secretion.
Piva F; Limonta P; Maggi R; Martini L
Neuroendocrinology; 1986; 42(6):504-12. PubMed ID: 3010157
[TBL] [Abstract][Full Text] [Related]
37. Altered sensitivity to an opiate antagonist, naloxone, in hyperprolactinemic male rats.
Sweeney CA; Morgan WW; Smith MS; Bartke A
Neuroendocrinology; 1985 Jul; 41(1):1-6. PubMed ID: 3895021
[TBL] [Abstract][Full Text] [Related]
38. Hypothalamic opioid receptors mediate the inhibitory actions of corticotropin-releasing hormone on luteinizing hormone release: further evidence from a morphine-tolerant animal model.
Nikolarakis KE; Almeida OF; Herz A
Brain Res; 1988 May; 450(1-2):360-3. PubMed ID: 2841006
[TBL] [Abstract][Full Text] [Related]
39. Apparent pA2 value of naltrexone is not changed in rats following continuous exposure to morphine or naloxone.
Paronis CA; Holtzman SG
Life Sci; 1992; 50(19):1407-16. PubMed ID: 1573974
[TBL] [Abstract][Full Text] [Related]
40. Age-related differences in the effect of chronic administration of naloxone on opiate binding in rat brain.
Bardo MT; Bhatnagar RK; Gebhart GF
Neuropharmacology; 1983 Apr; 22(4):453-61. PubMed ID: 6304564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
